Breast cancer Patients' vision under the microscope

NCT ID NCT06767462

Ongoing Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checks the eye health of people with breast cancer using standard tests like vision charts, eye exams, and scans. The goal is to spot any vision changes or eye damage that might happen during cancer treatment. About 160 participants will be followed to understand how breast cancer and its treatments affect the eyes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors monitor and protect vision in breast cancer patients during treatment.
What could go wrong: This is an observational safety study, not a treatment trial. It may not lead to direct changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPHTHALMIC SAFETY IN PATIENTS WITH BREAST CANCER

Contacts and locations

Locations

Research Site

La Jolla, California, 92093, United States
Research Site

Palo Alto, California, 94304, United States
Research Site

Iowa City, Iowa, 52242, United States
Research Site

Winston-Salem, North Carolina, 27104, United States
Research Site

Clairton, Pennsylvania, 15025, United States
Research Site

Pittsburgh, Pennsylvania, 15219, United States
Research Site

Sioux Falls, South Dakota, 57105, United States
Research Site

Bartlett, Tennessee, 38133, United States
Research Site

Houston, Texas, 77030, United States
Research Site

CABA, C1061, Argentina
Research Site

Córdoba, 5008, Argentina
Research Site

Leuven, 3000, Belgium
Research Site

Liège, 4000, Belgium
Research Site

Alfenas, 37130-000, Brazil
Research Site

Belo Horizonte, 30130-100, Brazil
Research Site

Curitiba, 80810-050, Brazil
Research Site

Lajeado, 95900000, Brazil
Research Site

Porto Alegre, 90050-170, Brazil
Research Site

Pouso Alegre, 37554-216, Brazil
Research Site

São Paulo, 01321-001, Brazil
Research Site

Sorocaba, 18060-105, Brazil
Research Site

Três Lagoas, 79601-001, Brazil
Research Site

Vitória, 29055-450, Brazil
Research Site

Montreal, Quebec, H2X 3E4, Canada
Research Site

Montreal, Quebec, H4A 3J1, Canada
Research Site

Santiago, 7500587, Chile
Research Site

Santiago, 7620157, Chile
Research Site

Ashdod, 7747629, Israel
Research Site

Nahariya, 2210001, Israel
Research Site

Lodz, 90-302, Poland
Research Site

Amadora, 2720-276, Portugal
Research Site

Braga, 4710-243, Portugal
Research Site

Seoul, 6351, South Korea
Research Site

Badalona, 08003, Spain
Research Site

Barcelona, 08028, Spain
Research Site

Barcelona, 08035, Spain
Research Site

Barcelona, 08036, Spain
Research Site

Girona, 17007, Spain
Research Site

L'Hospitalet de Llobregat, 08908, Spain
Research Site

Leganés, 28911, Spain
Research Site

Madrid, 28007, Spain
Research Site

Madrid, 28009, Spain
Research Site

Madrid, 28033, Spain
Research Site

Madrid, 28034, Spain
Research Site

Madrid, 28040, Spain
Research Site

Madrid, 28041, Spain
Research Site

Madrid, 28050, Spain
Research Site

Majadahonda, 28222, Spain
Research Site

Salamanca, 37007, Spain
Research Site

Sant Joan Despí, 08970, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.